Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | -$1.74M | -$2.55M | -$5.89M | -$7.70M | -$11.9M |
| Net income | -$1.15M | -$3.03M | -$6.59M | -$9.14M | -$11.7M |
| EPS (diluted) | — | -$0.29 | -$3.53 | -$82.60 | -$7.16 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$300K | -$2.71M | -$5.58M | -$7.33M | -$9.48M |
| Capital expenditures | — | — | $19.0K | — | — |
| Free cash flow | — | — | -$5.60M | — | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $505K | $8.42M | $2.58M | $1.92M | $334K |
| Total assets | $652K | $8.65M | $5.95M | $2.51M | $10.5M |
| Total liabilities | $2.28M | $976K | $1.90M | $1.80M | $8.22M |
| Long-term debt | $91.0K | — | — | — | — |
| Shareholders' equity | -$1.63M | $7.68M | $4.06M | $709K | $2.25M |
| Retained earnings | -$5.80M | -$8.89M | -$25.4M | -$34.6M | -$46.3M |
| Shares (wtd avg diluted) | 9.30M | 10.4M | 1.87M | 115K | 1.64M |
Every figure is extracted from Shuttle Pharmaceuticals Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.